News Detail
Maryland, 20 Sept 2024: From truckloads of torn documents to avian incursions in the production plant, Granules India’s recent manufacturing reprimand from the FDA is alarming no matter which way you look at it.
Earlier t......
View Details
Source : Fierce Pharma
Granules India
Biocon
Gland Pharma
ROVI
Form 483
U.S. FDA
FDA inspection
Manufacturing Facilities
India
Facilities
Fierce Pharma Homepage
Manufacturing
Pharma
Related News
- MBBS from abroad, started practicing medicine without passing FMGE, Registrations cancelled (08-11-2024)
- CM Flying raid on medicine shop in Sonipat, Chemist used to keep banned medicines in car (08-11-2024)
- One died, two serious after consuming Homeopathic medicine given by a quack, arrested (08-11-2024)
- DCA seizes ayurvedic medicine for misleading claims (08-11-2024)
- More cases against Ramdev, Acharya Balkrishna in Kerala (08-11-2024)
- India's Nutraceutical Sector Eyes Global Leadership with Strategic Policy Push (08-11-2024)
- Kerala launches campaign against misuse of antibiotics (08-11-2024)
- NCS Impounds 16 Containers of Illegal Drugs from India, UK, Canada (08-11-2024)
- US FDA proposes ending use of decongestant Phenylephrine (08-11-2024)
- Overpriced antibiotic ointment seized by DCA officials in Hyderabad (07-11-2024)